Pharmaceutical Technology

DECEMBER 15, 2022

In an expanded version of the sales forecast from GlobalData’s June 2022 publication, Cardiomyopathies: Global Drug Forecast and Market Analysis , the global cardiomyopathies market is expected to grow from $3.07bn last year to $9.63bn in 2031. of sales in 2021 and 2031 respectively. of global cardiomyopathies sales in 2021 and 31.2%

Marketing 130

Marketing Sales Clinical Trials Clinical Trials 130

Drug Discovery World

OCTOBER 26, 2022

A new method to study the proteins released by cells, which could lead to new biomarkers for diseases including cancer, has been developed by scientists at the Francis Crick Institute and Imperial College London. . The new method involves adding chemical tags to sugar molecules which are added to cells. Click’ chemistry .

Protein 52

Protein Genetics Containment Research 52

Pharmaceutical Technology

JULY 14, 2022

The commercial investment required to research and develop an innovative drug, prove its safety and efficacy, and bring it to market is staggering. Most famously, the US passed its Orphan Drug Act in 1983, providing innovators with financial motivation to develop orphan drugs and meet the needs of these forgotten patients.

Drugs 147

Drugs Medicine Marketing Development 147

World of DTC Marketing

SEPTEMBER 24, 2021

This drug was never about patients; it was about a company whose ego got too big and needed a savior in the form of a medicine that could bring in hundreds of millions of dollars. They had a new MS drug that was the talk of the industry and an exciting pipeline. I remember when Biogen was an exciting new biotech based in Westin.

Drugs 222

Drugs Pharma Companies Doctors Doctor 222

pharmaphorum

DECEMBER 24, 2021

The anti-amyloid drug, which also claimed a breakthrough tag from the FDA in July, is being developed for the treatment of early-stage Alzheimer’s disease. The $56,000-a-year price tag for the drug, which has now been cut in half in the US, also hasn’t helped the drugmakers make a case for Aduhelm with US payers.

Drugs 110

Drugs FDA Approval Trials Marketing 110

Rethinking Clinical Trials

JANUARY 17, 2024

The COVID Therapeutics Committee worked with the state health department to develop a policy for fair allocation of scarce medications to treat COVID-19. The first drug that used the new process was Remdesivir in May 2020. Through this work, UPMC learned that allocation does not actually mean receiving the drug.

Clinical Trials 169

Clinical Trials Clinical Trials Antibody Trials 169

World of DTC Marketing

SEPTEMBER 9, 2021

SUMMARY: Allowing Medicare to negotiate drug prices is popular with voters because the media has been focused on the high price of some drugs, but this measure won’t lead to lower healthcare costs. The drug industry is trying to convince voters that government negotiations with drug companies will lead to less innovation.

Drugs 222

Drugs Pharmacy Clinical Trials Clinical Trials 222

STAT News

MARCH 10, 2023

Enjoy, and see you soon … By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products , STAT explains. Two

Insulin 96

Insulin Pharmacy Pharma Companies Drugs 96

Drug Discovery World

OCTOBER 31, 2022

An update on the latest oncology developments by DDW Digital Content Editor Diana Spencer. Study reveals how stomach cancers develop drug resistance. Click’ chemistry used to tag proteins made by cancer cells. Epigenetics vital in predicting cancer drug outcomes. appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs Research Gene Editing Protein 52

pharmaphorum

OCTOBER 18, 2022

Medtech giant Beckton Dickinson (BD) has signed a deal with France’s Biocorp to use the latter’s near-field communication (NFC) tags in injectable devices. The Injay tag can confirm a complete injection and transfer that information via an NFC reader to a smartphone or tablet for review by a healthcare professional.

Drug Delivery 52

Drug Delivery Drugs Manufacturing Marketing 52

Rethinking Clinical Trials

FEBRUARY 14, 2024

Both drugs have a well-established safety profile and would be a good fit for a pragmatic design. The study started in June 2016 and ended in June 2022 and ultimately found no difference between the 2 drugs in preventing major CV outcomes and non-cancer death among hypertensive VA patients. 45% participants were from rural areas.

Clinical Trials 152

Clinical Trials Clinical Trials Cardiology Trials 152

Drug Discovery World

MARCH 2, 2023

A new paper has solved the 20-year mystery of how epigenetic modifications act as traffic lights to control gene expression and could ultimately speed up the development of a new class of epigenetic cancer drugs. But, until now, scientists lacked an understanding of what the chemical tag does, despite many years of research.

Gene Expression 52

Gene Expression Gene DNA RNA 52

pharmaphorum

APRIL 26, 2021

Technology firm Jolly Good and Teijin Pharma have begun a partnership to develop virtual reality digital therapeutics (VR DTx) for major depressive disorder. Jolly Good is a medical technology company that develops VR solutions and AI-based medical and welfare services that analyse user behaviour in the VR space.

Development 121

Development Medicine Production Marketing 121

pharmaphorum

JANUARY 5, 2022

The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status. Hutchmed’s drug is also being paired with Tagrisso and AZ’s PD-L1 blocker Imfinzi (durvalumab) in global registrational trials.

Antibody 110

Antibody Drugs Protein Gene 110

XTalks

APRIL 18, 2024

Roche has received Breakthrough Device designation from the US Food and Drug Administration (FDA) for its Elecsys pTau217 early Alzheimer’s blood test. This test, which is being co-developed with Eli Lilly, has the potential to facilitate earlier and more accurate detection of the disease.

Clinical Trials 52

Clinical Trials Clinical Trials In-Vitro Protein 52

Pharmaceutical Technology

FEBRUARY 22, 2023

The legal dispute is centered around rival cholesterol-lowering drugs produced by the two companies, which were approved in the summer of 2015. Developed by Sanofi and Regeneron, Praluent was approved by the FDA in July 2015. Both drugs are monoclonal antibodies that inhibit the protein PCSK9.

Antibody 262

Antibody Drugs Sales Protein 262

Rethinking Clinical Trials

DECEMBER 20, 2023

Yet enrollment of ethnic minorities in NIH clinical trials and for trials studying approved devices and drugs remains low. Approaches from the whole scientific community to tackle the inequality in workforce, trial leadership and trial participants have to be developed. We have to change how we are practicing.

Clinical Trials 169

Clinical Trials Clinical Trials Trials Cardiology 169

Drug Discovery World

JULY 25, 2023

DDW recently hosted Where are the breakthroughs in mRNA drug discovery and development? In this webinar, sponsored by Elegen, attendees learnt about the breakthroughs in mRNA drug discovery and development. The post Further insight into breakthroughs in mRNA drug discovery appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs Packaging Packaging Manufacturing 52

Drug Discovery World

NOVEMBER 7, 2022

Scientists have uncovered a critical feature that a promising new class of cancer drugs, known as CELMoDs, needs to be effective. . In the study, reported in Science, researchers discovered that these drugs, in order to work, need to cause a critical shape-change in cereblon when they bind to it. Understanding the problem.

Scientist 52

Scientist Drugs Protein Research 52

Rethinking Clinical Trials

FEBRUARY 28, 2024

But there are concerns to developing DCTs including lack of standardization and validation, regulatory and ethical uncertainties, engagement vs. coercion, data security and privacy issues, technological literacy and access, resistance to change and adoption, and lack of “safe” sharing. from 2021 to 2026.

Clinical Trials 141

Clinical Trials Clinical Trials Trials Clinical Research 141

pharmaphorum

NOVEMBER 16, 2021

NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharma’s Ontozry. An opinion from the Scottish Medicine Consortium (SMC) on the use of the drug by NHS Scotland is expected to be published early in 2022.

Drugs 96

Drugs Medicine Clinical Trials Clinical Trials 96

pharmaphorum

APRIL 20, 2021

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator. . The Scottish Medicines Consortium is expected to publish its final advice on the drug later this year. billion by 2028.

Sales 110

Sales Medicine Drugs Marketing 110

Drug Discovery World

NOVEMBER 28, 2023

An experimental drug has shown potential as a disease-modifying therapy for Parkinson’s disease, according to a new study published in Nature Communications. Mission Therapeutics develops therapeutics that promote mitophagy, which enables the removal of dysfunctional mitochondria, thereby improving cell health and function.

In-Vivo 52

In-Vivo Protein Drugs Research 52

Drug Discovery World

DECEMBER 20, 2022

The clinical development of etranacogene dezaparvovec was led by uniQure and sponsorship of the clinical trials transitioned to CSL after it licensed global rights to commercialise the treatment. . World’s most expensive drug. million, making it the world’s most expensive drug. .

Gene Therapy 52

Gene Therapy Gene Clinical Trials Clinical Trials 52

Rethinking Clinical Trials

OCTOBER 26, 2023

There are possible clinical research components that would include research on treatment during pregnancy, vaccine development, and implementation model research. A manuscript is under development. with the rate of reported acute Hepatitis C cases increasing 400% during 2010-2020.

Clinical Research 141

Clinical Research Clinical Trials Clinical Trials Research 141

XTalks

DECEMBER 13, 2023

The US Food and Drug Administration (FDA) has approved the first gene therapies for the treatment of sickle cell disease, approving two on the same day. The landmark approvals were awarded to bluebird bio’s Lyfgenia (lovo-cel) and Vertex Pharmaceuticals and CRISPR Therapeutics’ jointly developed Casgevy (exa-cel).

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

pharmaphorum

AUGUST 25, 2022

Johnson & Johnson has its first worldwide regulatory approval – in the EU – for Tecvayli, one of two much-anticipated bispecific antibodies the drugmaker has developed for patients with multiple myeloma. Tecvayli previously scored a priority medicines (PRiME) designation from the EMA and a breakthrough-therapy tag from the FDA.

Antibody 98

Antibody Marketing Drugs Medicine 98

Drug Discovery World

JANUARY 9, 2023

Harvard investigators have developed a new cell therapy approach to eliminate established tumours and induce long-term immunity. . Using gene engineering, we are repurposing cancer cells to develop a therapeutic that kills tumour cells and stimulates the immune system to both destroy primary tumors and prevent cancer.” .

Scientist 52

Scientist Gene Editing Gene Engineer 52

pharmaphorum

AUGUST 21, 2022

NMDA antagonist dextromethorphan is an ingredient found in cough syrups, while bupropion is an established antidepressant that was originally developed by GSK and sold as Wellbutrin. However, it has a broader label as unlike J&J’s drug it is indicated for use in previously-untreated MDD. Photo by Sydney Sims on Unsplash.

Drugs 98

Drugs FDA Approval Production Marketing 98

The Pharma Data

JANUARY 31, 2021

These findings give confidence that Clover’s COVID-19 vaccine candidates are suitable for further clinical development.” Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. About Trimer-Tag© Technology. —- End —-.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Rethinking Clinical Trials

AUGUST 28, 2023

 Speakers Prof Sir Martin Landray, FMedSci Professor of Medicine & Epidemiology University of Oxford Chief Executive, Protas Khair ElZarrad, PhD, MPH Director, Office of Medical Policy Center for Drug Evaluation and Research (CDER) U.S. The new structure aims to provide clarity and better readability.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

Rethinking Clinical Trials

AUGUST 28, 2023

 Speakers Prof Sir Martin Landray, FMedSci Professor of Medicine & Epidemiology University of Oxford Chief Executive, Protas Khair ElZarrad, PhD, MPH Director, Office of Medical Policy Center for Drug Evaluation and Research (CDER) U.S. The new structure aims to provide clarity and better readability.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

pharmaphorum

DECEMBER 23, 2021

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. HER3 is expressed in more than 80% of EGFR-mutant NSCLC, and overexpression is associated with poor outcomes, but no HER3-targeted drugs have been approved to date.

Drugs 71

Drugs Antibody Clinical Trials Clinical Trials 71

Drug Discovery World

MAY 22, 2023

While the global economic landscape faces a major crisis and biotech is not recession-proof, cell and gene therapy (CGT) has continued to progress with acquisitions, breaking ground on new facilities and approvals across the year – not limited to the breakout of the world’s most expensive drug. But are these price tags a barrier to access?

Gene Therapy 52

Gene Therapy Gene Drugs Contamination 52

pharmaphorum

JANUARY 11, 2022

A prescription digital therapeutic (DTx) for leukaemia patients developed by Blue Note Therapeutics has been awarded breakthrough device status by the FDA. Breakthrough designations can speed up the development of new therapies, making them available to patients sooner.

Development 63

Development Production Drugs 63

XTalks

JULY 12, 2021

The US Food and Drug Administration’s (FDA) recent approval of Biogen’s Alzheimer’s drug Aduhelm (aducanumab) was met with a lot of backlash, prompting the health agency to narrow its recommendation of the drug for mild forms of the disease. head of research and development at Biogen, in a statement from the company.

Drugs 98

Drugs Clinical Trials Clinical Trials Trials 98

pharmaphorum

NOVEMBER 19, 2020

Novartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its US patent expired this year – and Samsung Bioepis and Biogen are closing in after the FDA accepted a filing for their cut-price rival.

FDA Approval 63

FDA Approval Marketing Drugs Clinical Development 63